Abbott India Namita Shah - Associate Director - New Product Introduction and Therapy Area Strategy to step down
Mumbai: Abbott India has announced that Namita Shah - Associate Director - New Product Introduction and Therapy Area Strategy, has tendered her resignation from employment of the Company with effect from the close of business hours of April 15, 2025.
She has resigned to pursue opportunities outside the Company.
Following her resignation, she will also cease to be the Senior Management Personnel of the Company effective the said date, the Company informed in a BSE filing.
Namita joined the Company in October 2021 as Associate Director - New Product Introductions and Therapy Area Strategy. She is a result oriented pharmaceutical professional with an enriching experience of over 25 years in Pharmaceutical and Healthcare business. Prior to joining Abbott, Namita was associated with Sun Pharma as GM Portfolio Management. She has also worked with Wockhardt; Alkem Laboratories; Indoco Remedies; Ipca Labs; Charak Pharma and Lupin Laboratories.
She has completed her Bachelor’s in Pharmacy from Mumbai University and Diploma in Management Studies from NMIMS.
Read also: Abbott India Gets CDSCO Panel Nod To Conduct Phase III CT of Ursodeoxycholic Acid tablet
Headquartered in Mumbai, Abbott India Limited, a publicly listed company and a subsidiary of Abbott Laboratories The Company offers medicines in multiple therapeutic categories such as women's health, gastroenterology, cardiology, metabolic disorders and primary care.
Abbott India Limited is part of Abbott's global pharmaceutical business in India.
Read also: Abbott agrees to global continuous glucose monitoring litigation settlement with Dexcom
